Results 111 to 120 of about 382,319 (316)

Effectiveness of rTMS on Working Memory and Inhibitory Impairments in Patients With Post‐Stroke Executive Deficits

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Considerable efforts have been dedicated to developing effective treatments for post‐stroke executive impairment (PSEI), among which repetitive transcranial magnetic stimulation (rTMS) has shown great potential. This study aimed to investigate the therapeutic effects of high‐frequency rTMS on working memory (WM) and response ...
Mengting Lao   +6 more
wiley   +1 more source

Jacob Dahl Rendtorff, Responsibility, Ethics and Legitimacy of Corporations (Copenhagen: Copenhagen Business School Press, 2009)

open access: yesNordicum-Mediterraneum, 2011
Review of Jacob Dahl Rendtorff's book Responsibility, Ethics and Legitimacy of Corporations (Copenhagen: Copenhagen Business School Press. 2009).
Maria Pia Paganelli
doaj  

Longitudinal Assessment of Biomarkers in ALS: Discriminative Biomarkers for Disease Progression and Survival

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To assess the association and discriminative performance of serum biomarkers with clinical disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Methods This retrospective study, conducted at Houston Methodist Hospital, Houston, TX, used longitudinal serum samples collected between January 2018 and ...
David R. Beers   +7 more
wiley   +1 more source

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak   +4 more
wiley   +1 more source

Traveling Through Corporate Time: Inevitability and (Anti-) Corporate Narrative Form

open access: yesNANO, 2015
I argue that the trope of time travel is an essential component of the corporation’s narrative machinery. To be clear, I am not suggesting time travel as a metaphor or figure for how the corporation operates, but rather as a vital part of its narrative ...
Adam Haley
doaj  

The Separation of Ownership and Control in East Asian Corporations

open access: yes, 2000
S. Claessens   +2 more
semanticscholar   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket   +14 more
wiley   +1 more source

CORPORATE SOCIAL RESPONSIBILITY: PERFORMANCE AND REPORTING

open access: yesSosyal Ekonomik Araştırmalar Dergisi, 2008
Şirketlerin sosyla sorumluluğu kavramı yeni değildir. Bir şirketin ana amacı en az maliyet ile en çok gelir elde etmektir. Öte taraftan etik değerlere önem veren işadamları halka ve kendilerine karşı sorumluluklarının da bilincinde olurlar.
Meltem Tumay
doaj  

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy